Endometriosis is a chronic and often painful condition in which tissue similar to the lining inside the uterus — the endometrium — grows outside the uterus. This misplaced tissue can be found on the ovaries, fallopian tubes, and the pelvic lining. It thickens, breaks down, and bleeds with each menstrual cycle, but because it has no way to exit the body, it becomes trapped. This can lead to the formation of cysts, scar tissue, and adhesions, causing pain, inflammation, and, in some cases, infertility. Current treatments, which include hormonal therapies and surgery, can be effective but often come with significant side effects or are not a permanent solution. This has led researchers to explore new therapeutic avenues, with peptide therapy emerging as a particularly exciting and promising area of investigation.
The Challenge of Treating Endometriosis
One of the main challenges in treating endometriosis is that the growth of endometrial tissue is driven by estrogen. This is why many of the current treatments focus on suppressing estrogen production or blocking its effects. However, these hormonal therapies can have significant side effects, including menopausal symptoms, bone loss, and mood changes. Surgery to remove the endometrial lesions can be effective, but it is an invasive procedure, and the lesions can often grow back.
Peptides: A Targeted and Non-Hormonal Approach
Peptide therapy offers a new and innovative approach to treating endometriosis that is both targeted and non-hormonal. Peptides are short chains of amino acids that act as signaling molecules in the body. By designing peptides that specifically target the endometrial lesions, it is possible to deliver a therapeutic effect directly to the site of the disease, while minimizing side effects in other parts of the body.
ENDO-205: A Precision Peptide Therapeutic
One of the most promising peptide therapies in development for endometriosis is ENDO-205. This first-in-class, non-hormonal targeted peptide therapeutic is designed to act directly on the diseased endometriosis tissue, eliminating the lesions at their origin. [1] By targeting the lesions directly, ENDO-205 has the potential to provide a more effective and long-lasting treatment than current therapies, without the side effects of hormonal suppression. The FDA has recently cleared an Investigational New Drug (IND) application for ENDO-205, paving the way for clinical trials in women with endometriosis. [2]
CGRP Antagonists: Targeting Pain and Lesion Growth
Calcitonin Gene-Related Peptide (CGRP) is a neuropeptide that is involved in pain transmission and inflammation. Recent research from Harvard Medical School has found that blocking CGRP can not only decrease pain sensitivity in endometriosis but also reduce the size of the lesions. [3] This suggests that CGRP antagonists, which are already used to treat migraines, could be a new and effective treatment for endometriosis-related pain.
Other Promising Peptides
Other peptides that have shown promise in preclinical studies for endometriosis include:
- Short synthetic endostatin peptides: These peptides have been shown to inhibit the growth of new blood vessels, which are essential for the growth of endometrial lesions. [4]
- BPC-157: This peptide is known for its anti-inflammatory and regenerative properties and has been anecdotally reported to help with endometriosis symptoms. [5]
Comparing Peptides for Endometriosis
| Peptide/Target | Mechanism of Action | Potential Benefits for Endometriosis | Development Stage | Citations |
|---|---|---|---|---|
| ENDO-205 | Targets and eliminates endometriosis lesions directly. | Lesion removal, pain and inflammation reduction. | Clinical Trials | [1], [2] |
| CGRP Antagonists | Blocks the action of CGRP, a pain-related neuropeptide. | Reduces pain and lesion size. | Preclinical | [3] |
| Endostatin Peptides | Inhibit the growth of new blood vessels. | May inhibit the growth of endometrial lesions. | Preclinical | [4] |
| BPC-157 | Anti-inflammatory and regenerative properties. | May reduce inflammation and promote tissue healing. | Anecdotal | [5] |
Key Takeaways
- Peptide therapy offers a new and promising approach to treating endometriosis that is both targeted and non-hormonal.
- ENDO-205 is a first-in-class peptide therapeutic that is designed to eliminate endometriosis lesions at their source.
- CGRP antagonists may be an effective treatment for endometriosis-related pain.
- Other peptides, such as endostatin peptides and BPC-157, have also shown promise in preclinical studies.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] EndoCyclic Therapeutics. (n.d.). Peptide Platform. Retrieved from https://www.endocyclictherapeutics.com/peptide
[2] Contemporary OB/GYN. (2026, March 23). FDA clears ENDO-205 Investigational New Drug application for endometriosis. Retrieved from https://www.contemporaryobgyn.net/view/fda-clears-endo-205-investigational-new-drug-application-for-endometriosis
[3] BioWorld. (2024, November 7). Blocking CGRP in endometriosis: two birds with one stone? Retrieved from https://www.bioworld.com/articles/714198-blocking-cgrp-in-endometriosis-two-birds-with-one-stone
[4] Nap, A. W., Dunselman, G. A., Griffioen, A. W., Mayo, K. H., & Evers, J. L. (2005). Short synthetic endostatin peptides inhibit endothelial cell proliferation and angiogenesis. Fertility and Sterility, 84(1), 223-230. https://www.sciencedirect.com/science/article/pii/S0015028205034345
[5] Reddit. (2020, September 18). Self administration BPC-157 and high quercetine dosage. Retrieved from https://www.reddit.com/r/endometriosis/comments/iv5t63/self_administration_bpc157_and_high_quercetine/
